Novome announces phase 1 trial of GEMM cell therapy

Novome announces phase 1 trial of GEMM cell therapy

Novome Biotechnologies announced the beginning of its phase 1 trial evaluating NOV-001, a once-daily Genetically Engineered Microbial Medicine for the treatment of enteric hyperoxaluria.“With this significant milestone, we are advancing toward our goal of becoming a leader in the field of living therapeutics,” Blake Wise, CEO of Novome said in a press release. “We believe that our Genetically Engineered Microbial Medicine (GEMM) cell therapies hold tremendous potential for patients across a wide range of diseases, including ulcerative colitis and irritable bowel syndrome, inRead More

Share on facebook
Share on twitter
Share on linkedin